Scott T. Reents - Feb 23, 2024 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role: EVP, CHIEF FINANCIAL OFFICER
Signature: T.O. Odutayo, attorney-in-fact for Scott T. Reents
Stock symbol: ABBV
Transactions as of: Feb 23, 2024
Transactions value $: -$4,591,371
Form type: 4
Date filed: 3/1/2024, 05:50 PM
Previous filing: Feb 20, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABBV	Common Stock, $0.01 par value	Options Exercise	$868K	+14.1K	+52.24%	$61.36	41.2K	Feb 23, 2024	Direct
transaction	ABBV	Common Stock, $0.01 par value	Sale	-$2.51M	-14.1K	-34.32%	$177.44	27.1K	Feb 23, 2024	Direct	F1
transaction	ABBV	Common Stock, $0.01 par value	Tax liability	-$2.08M	-11.6K	-42.99%	$178.99	15.4K	Feb 28, 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABBV	Option (Right to buy)	Options Exercise	-$868K	-14.1K	-44.86%	$61.36	17.4K	Feb 23, 2024	Common Stock	14.1K	$61.36	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.41 to $177.55, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Content

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.41 to $177.55, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.